Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.59 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | AVPR2 known ✓ | P30518 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.59 |
| ▸ | FPR2 | P25090 | 4/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 3/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31337069 | 1.00 | MEN1 (0.59) | MEN1BLMKMT2AUSP2POLB | |
| Hydrochloric Acid SCHEMBL29354092 | 0.99 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Hydrochloric Acid SCHEMBL30207638 | 0.99 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Hydrochloric Acid SCHEMBL18617 | 0.99 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| SCHEMBL29593395 | 0.98 | MEN1 (0.61) | MEN1BLMKMT2AUSP2POLB | |
| SCHEMBL3903552 | 0.98 | MEN1 (0.61) | MEN1BLMKMT2AUSP2POLB | |
| Perchlorate SCHEMBL31688153 | 0.95 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Acetic Acid SCHEMBL29510237 | 0.95 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Hydrochloric Acid SCHEMBL3506817 | 0.94 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Piperazine SCHEMBL1317991 | 0.94 | MEN1 (0.55) | MEN1BLMKMT2AUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3014274-B1 | RATIOMETRIC ASSAY FOR HYDROLYTIC ENZYME QUANTIFICATION | FUNDACIÓ INST CATALÀ D'INVESTIGACIÓ QUÍMICA (ES) | 2017-08-09 | — | — | EP | disclosed |
| US-9511064-B2 | Combination therapy for the treatment of cancer and immunosuppression | BASILEA PHARMACEUTICA AG (CH) | 2016-12-06 | — | — | US | disclosed |
| US-20160139137-A1 | RATIOMETRIC ASSAY FOR HYDROLYTIC ENZYME QUANTIFICATION | INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ES) | 2016-05-19 | — | — | US | disclosed |
| EP-3014274-A1 | RATIOMETRIC ASSAY FOR HYDROLYTIC ENZYME QUANTIFICATION | Fundació Institut Català D'investigació Quimica (ES) | 2016-05-04 | — | — | EP | disclosed |
| US-20150157622-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | BASILEA PHARMACEUTICA AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150157623-A1 | COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | UNI OF BASEL (CH) | 2015-06-11 | — | — | US | disclosed |
| EP-2872505-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | Basilea Pharmaceutica AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| CN-104603133-A | Combination therapy for the treatment of cancer and immunosuppression | BASILEA PHARMACEUTICA AG | 2015-05-06 | — | — | CN | disclosed |
| US-8993587-B2 | Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression | UNIVERSITAT BASEL (CH) | 2015-03-31 | — | — | US | disclosed |
| EP-2818868-A1 | Ratiometric assay for hydrolytic enzyme quantification | Fundació Institut Català d'Investigació Química (ES) | 2014-12-31 | — | — | EP | disclosed |
| WO-2014206918-A1 | RATIOMETRIC ASSAY FOR HYDROLYTIC ENZYME QUANTIFICATION | FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ICIQ) (ES) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014009222-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | BASILEA PHARMACEUTICA AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| EP-2663298-A1 | COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | Universität Basel (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20130281478-A1 | COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | UNIVERSITAT BASEL (CH) | 2013-10-24 | — | — | US | disclosed |
| WO-2012095379-A1 | COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | UNIVERSITÄT BASEL (CH) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157623-A1 | COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | SHMT2, MAVS, COX5A | PPARG 3727/4885CHRM1 3534/4885AVPR2 4767/4885 |
| US-20130281478-A1 | COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | SHMT2, MAVS, COX5A | PPARG 3727/4885CHRM1 3534/4885AVPR2 4767/4885 |
| US-20150157622-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | MAVS, NDUFAF1, TFAM | PPARG 2290/4885CHRM1 3011/4885AVPR2 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.